Correction: Comparing efficacy and safety of P013, a proposed pertuzumab biosimilar, with the reference product in HER2-positive breast cancer patients: a randomized, phase III, equivalency clinical trial (BMC Cancer, (2022), 22, 1, (960), 10.1186/s12885-

نویسندگانAllahyari, A., Ehsanpour, A., Najafi, B., (...), Kaf, H., Najaf, S.
نشریهBMC Cancer,
نوع مقالهFull Paper
تاریخ انتشار2022-12-1
رتبه نشریهISI
نوع نشریهچاپی
کشور محل چاپایران

چکیده مقاله